Last update Feb. 11, 2019

Loxoprofène Sodique

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

A non-steroidal anti-inflammatory derivative of propionic acid with prostaglandin inhibitory effect due to non-selective inhibition of cyclo-oxygenase, used in the oral and topical treatment of pain and inflammatory and febrile processes.
Oral administration, one to three times a day.

Since the last update date we have not found published data on its excretion in breastmilk.

Its pharmacokinetic data - high percentage of protein binding, short life (DrugInfo 2018, Helmy 2013, Jhee 2007) and low pKa - means it is unlikely for there to be transfer to milk in significant amounts.

Until there is more published data on this drug in relation to breastfeeding, safer alternatives may be preferred, especially during the neonatal period and in cases of prematurity.

Alternatives

  • Ibuprofen ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Loxoprofène Sodique is Loxoprofen Sodium in French.

Is written in other languages:

Group

Loxoprofène Sodique belongs to this group or family:

Tradenames

Main tradenames from several countries containing Loxoprofène Sodique in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 95 %
Molecular weight 304 daltons
Protein Binding 98 %
VD 0.16 l/Kg
pKa 4.2 -
Tmax 0.5 - 0.8 hours
1.3 - 1.6 hours

References

  1. Drug Information System. Loxoprofen. Drug Monograph 2018 Full text (link to original source) Full text (in our servers)
  2. Helmy SA. Pharmacokinetics and Bioequivalence Evaluation of 2 Loxoprofen Tablets in Healthy Egyptian Male Volunteers. Clin Pharmacol Drug Dev. 2013 Abstract
  3. Saja Pharm. Loxoprofen. Drug Summary 2012 Full text (in our servers)
  4. Jhee OH, Lee MH, Shaw LM, Lee SE, Park JH, Kang JS. Pharmacokinetics and bioequivalence study of two brands of loxoprofen tablets in healthy volunteers. Arzneimittelforschung. 2007 Abstract

Total visits

1,499

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM